echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > $1 billion to develop innovative protein degradation therapies

    $1 billion to develop innovative protein degradation therapies

    • Last Update: 2021-03-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    yesterday, AbbVie and Frontier Pharmaceuticals jointly announced a global strategic partnership that will jointly identify, develop and commercialize innovative small-molecule drug pipelines for "non-essential" protein targets using Frontier's unique chemical proteomics technology platform.In the field of drug development, "non-drugable" means that the protein surface does not have a place for small molecule compounds to bind, so small molecule drugs cannot be targeted. Currently, up to 90% of the 20,000 or so proteins in the human body fall into this category.These "non-drug-resistant" proteins may appear in temporary "pockets" when encountering other binding proteins in cells, but they exist for a short period of time and disappear after the protein has functioned. Frontier Medicines' chemical proteomics platform uses covalent probes to detect short-lived binding points on proteins. In theory, the technology platform is designed with co-price compounds capable of targeting 50% of the "non-drugable" protein group. The company is also developing targeted protein degradation technology based on E3 ubibin connective enzymes, which, in combination with these co-priced compounds, can degrade "non-drugable" targets into the proteases of cells. The company was named Biotech Mammoth of the Year last year.Under the agreement, AbbVie will pay Frontier $55 million in upfront payments, as well as part of frontier's preclinical development costs. The two sides will work together to advance scientific discovery and preclinical development projects for E3 connective enzymes, immunology and oncology targets. After successfully reaching the intended preclinical development phase, AbbVie will be responsible for the subsequent global development and commercialization of the project. Frontier is eligible for milestone payments that could exceed $1 billion. (Pharmaceutical Mingkang): 1 AbbVie and Frontier Pharmaceuticals Company Global Partnership to Discover And Develop Novel Therapies and E3 Degradersst Again-To-Drug Targets. Retrieved December 2, 2020, from
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.